Covid
- Thread starter texasguyto
- Start date
bump for current events coverage..
judging by those numbers, it appears that the
covid virus might be more deadly to older folks,
and if i'm interpreting it correctly,
people under the age of 70 fare much better
..perhaps this information could be utilized by
our political leaders to "allow" citizens to
go back to school and work..
just a thought.
judging by those numbers, it appears that the
covid virus might be more deadly to older folks,
and if i'm interpreting it correctly,
people under the age of 70 fare much better
..perhaps this information could be utilized by
our political leaders to "allow" citizens to
go back to school and work..
just a thought.
current events discussing covid treatment
"Yet curiously absent amid repeated indictments of HCQ is this critical discovery, hiding in plain sight:
Studies have repeatedly shown that HCQ combined with azithromycin (with or without zinc) has yielded positive results in one specific population:
high-risk patients (over 60, diabetes, obesity, etc.) receiving the treatment
before progression of the disease into the lungs."
"Yet curiously absent amid repeated indictments of HCQ is this critical discovery, hiding in plain sight:
Studies have repeatedly shown that HCQ combined with azithromycin (with or without zinc) has yielded positive results in one specific population:
high-risk patients (over 60, diabetes, obesity, etc.) receiving the treatment
before progression of the disease into the lungs."
"The benefit of using a combination therapy of HCQ, azithromycin and zinc in the earliest stages of the COVID-19 illness is not surprising.
The three components interact to
block the virus from entering the cells of the respiratory system and reproducing.
They also stimulate the body to produce virus-killing proteins and hormones
and help to mediate some of the symptoms.
They are most effective early in the course of disease
when the infection is limited to the upper respiratory system.
Once the virus reaches the lungs the disease becomes very difficult to treat."
The three components interact to
block the virus from entering the cells of the respiratory system and reproducing.
They also stimulate the body to produce virus-killing proteins and hormones
and help to mediate some of the symptoms.
They are most effective early in the course of disease
when the infection is limited to the upper respiratory system.
Once the virus reaches the lungs the disease becomes very difficult to treat."
Plandemic. It's the OH MY GOD I HAVE SPENT THE LAST 4 YEARS DOING NOTHING BUT BITCH virus. It's the we are so lost we couldn't possibly run a normal campaign with a dementia ridden 47 year Washington insider virus.
"The endless debate over the safety of these drugs for use in COVID-19 patients is
nonsensical.
A search of the FDA’s publicly available adverse events data base shows that over the last 50 years, of the billions of uses of HCQ around the world, there have only been 202 reported cases of cardiac-related deaths. This is an astounding safety record! And even if one were to assume that 95% of cardiac-related deaths have not been reported, it’s still a vanishingly small percentage of total uses. Azithromycin has an even better safety record, and zinc is a non-prescription vitamin supplement."
nonsensical.
A search of the FDA’s publicly available adverse events data base shows that over the last 50 years, of the billions of uses of HCQ around the world, there have only been 202 reported cases of cardiac-related deaths. This is an astounding safety record! And even if one were to assume that 95% of cardiac-related deaths have not been reported, it’s still a vanishingly small percentage of total uses. Azithromycin has an even better safety record, and zinc is a non-prescription vitamin supplement."
"Physicians treating COVID-19 patients should
tune out the politics of HCQ and
“follow the science.”
HCQ combined with azithromycin and zinc has shown safety and efficacy in high risk patients treated early in their disease.
Moreover, because this therapy can be used very early in the disease progression, l
ong before other treatments are used,
it removes the dilemma of "treatment A vs. treatment B."
A patient can later be given other more aggressive treatments
if the early use of HCQ does not deliver the desired reduction in symptoms and virus load.
There is, of course, a small population for which HCQ or azithromycin should not be prescribed due to pre-existing conditions.
But, other than these few exceptions,
widespread adoption of this drug regimen,
in the right patient population,
will save many lives
and should be strongly recommended,
indeed encouraged,
by our medical and regulatory establishments."
tune out the politics of HCQ and
“follow the science.”
HCQ combined with azithromycin and zinc has shown safety and efficacy in high risk patients treated early in their disease.
Moreover, because this therapy can be used very early in the disease progression, l
ong before other treatments are used,
it removes the dilemma of "treatment A vs. treatment B."
A patient can later be given other more aggressive treatments
if the early use of HCQ does not deliver the desired reduction in symptoms and virus load.
There is, of course, a small population for which HCQ or azithromycin should not be prescribed due to pre-existing conditions.
But, other than these few exceptions,
widespread adoption of this drug regimen,
in the right patient population,
will save many lives
and should be strongly recommended,
indeed encouraged,
by our medical and regulatory establishments."
"Given the safety profile and apparent benefit of
using HCQ in the right patient population,
why has the drug become so bitterly contested?
It is hard to understand why the FDA
has yet to issue an emergency use authorization
for HCQ and azithromycin
in the above-described population.
People are dying."
Alan C. Herman earned his Ph.D. in Microbiology from Duke University and did his post-doctoral work in oncogenic virus structure. From 2011 to his retirement in 2018, he served as chief scientific officer for Coherus Biosciences.
using HCQ in the right patient population,
why has the drug become so bitterly contested?
It is hard to understand why the FDA
has yet to issue an emergency use authorization
for HCQ and azithromycin
in the above-described population.
People are dying."
Alan C. Herman earned his Ph.D. in Microbiology from Duke University and did his post-doctoral work in oncogenic virus structure. From 2011 to his retirement in 2018, he served as chief scientific officer for Coherus Biosciences.
"When these patients received the combination therapy
prior to hospitalization
—shortly after, or even before a confirmed COVID-19 diagnosis—
they had more rapid viral clearance,
lower hospitalization rates,
fewer intubations,
and lower mortality.
High-risk patients should
discuss this potential treatment with their physician
well in advance of contracting COVID-19
so that, should symptoms occur,
a course of early treatment with
HCQ will already have been mutually agreed upon."
prior to hospitalization
—shortly after, or even before a confirmed COVID-19 diagnosis—
they had more rapid viral clearance,
lower hospitalization rates,
fewer intubations,
and lower mortality.
High-risk patients should
discuss this potential treatment with their physician
well in advance of contracting COVID-19
so that, should symptoms occur,
a course of early treatment with
HCQ will already have been mutually agreed upon."
"seems to be safe, regardless of clinical setting"
Sept 25, 2020
"Hydroxychloroquine is not associated with an abnormal amount of arrhythmic events among COVID-19 patients, according to a brand new analysis out of Europe.
The study, published in EP Europace, includes data from 649 COVID-19 patients treated with the drug."
Sept 25, 2020
"Hydroxychloroquine is not associated with an abnormal amount of arrhythmic events among COVID-19 patients, according to a brand new analysis out of Europe.
The study, published in EP Europace, includes data from 649 COVID-19 patients treated with the drug."
28.09.20. ‘Criminal’ ban on hydroxychloroquine based on ‘faulty’ study. Liberal MP Craig Kelly says the ban placed on COVID-19 treatment hydroxychloroquine by Australian bureaucrats violates the Hippocratic Oath taken by doctors and is based on a study since proven false. Mr Kelly said health bureaucrats interfered in the doctor-patient relationship by prohibiting the use of hydroxychloroquine even if the doctor thought the treatment would save the patient’s life. Health bureaucrats have “violated the very first principle of the Hippocratic oath” which is to ‘do no harm’,” he said. Mr Kelly told Sky News technically bureaucrats should only ban the use of hydroxychloroquine if the evidence shows beyond all reasonable doubt that firstly, hydroxychloroquine doesn’t work and secondly, that it is dangerous. “Recent studies show that proposition is no longer sustainable … and they must lift their bans otherwise they are engaged in crimes against humanity and they should be taken to the criminal court in the Hague,” he said. “They are withholding medical treatment from Australians that the evidence shows can save their lives
” Mr Kelly also said the National COVID-19 Clinical Evidence Task Force which made the authoritative decision banning hydroxychloroquine rely upon the results of a flawed study conducted at the Oxford University. He argued the study ultimately gave patients “double the dose of what they know is an overdose” and the director of the study stated doses were based on amoebic dysentery dose rates. Sky News host Rowan Dean said the director made “clear amoebic dysentery is what they based their doses on, but we know hydroxychloroquine is never used for amoebic dysentery”. “The bottom line is the study was flawed,” he said. “(French newspaper) France Soir themselves say the recovery study cannot be considered serious and yet that is the study all Australian medical advice is based upon by the words of the COVID task force themselves who say the vast majority of evidence is from the recovery trial.”
” Mr Kelly also said the National COVID-19 Clinical Evidence Task Force which made the authoritative decision banning hydroxychloroquine rely upon the results of a flawed study conducted at the Oxford University. He argued the study ultimately gave patients “double the dose of what they know is an overdose” and the director of the study stated doses were based on amoebic dysentery dose rates. Sky News host Rowan Dean said the director made “clear amoebic dysentery is what they based their doses on, but we know hydroxychloroquine is never used for amoebic dysentery”. “The bottom line is the study was flawed,” he said. “(French newspaper) France Soir themselves say the recovery study cannot be considered serious and yet that is the study all Australian medical advice is based upon by the words of the COVID task force themselves who say the vast majority of evidence is from the recovery trial.”
